Dabigatran: Laboratory monitoring

Pathology

Volumn 44, Issue 6, 2012, Pages 578-580

  Jones, Simon D F ^a   Eaddy, Nicola S ^a   Chan, George T C ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866924538     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835833f4     Document Type: Article

References (6)

1. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 2011; 49: 755-7.
2. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assay s and reversal of anticoagulant activity. Thromb Haemost 2011; 103: 1116-27.
3. Hyphen Biomed. Hemoclot Thrombin-Inhibitors package insert. Ref CK002L. Paris: Hyphen Biomed, 2010.
4. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-42.
5. Weigel G, Loacker LJ, Griesmacher A, et al. Interference of routine coagulation tests with the new oral anticoagulant dabigatran - A multicenter study. Poster presentation P17-16. Gesellschaft für Thrombose und Hämostaseforschung (GTH), Wiesbaden, Germany, 16-19 February 2011.
6. Lindahl TL, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-8.